Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PARP Inhibitor BGB-290 · 1 trial · 10 indications
Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.
| Arm | Type | Description |
|---|---|---|
| Arm A (Pamiparib (BGB-290), Temozolomide (TMZ)) | EXPERIMENTAL | Participants with grades III-IV newly diagnosed IDH1/2 mutant glioma receive 60mg pamiparib (BGB-290) PO BID on days 1-28 and 20mg temozolomide (TMZ) PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity. |
| Arm B (BGB-290, Temozolomide) | EXPERIMENTAL | Participants with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor pamiparib (BGB-290) PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Cohort B0: Participants who are surgical candidates with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID for 7 days, pre-surgery. After recovery from surgery, participants receive PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| PARP Inhibitor BGB-290 | DRUG | Given PO |
| Temozolomide (TMZ) | DRUG | Given PO |
Inclusion Criteria: * Arm A Only: Participants must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma. * Arm B Only: WHO grades I-IV recurrent IDH1/2 mutant glioma. Participants in Arm B must have magnetic resonance imaging (MRI) confirm...
PARP Inhibitor BGB-290 is an investigational small molecule being studied for the treatment of glioblastoma, including recurrent glioblastoma, as well as other IDH1/2-mutant gliomas. It is currently in Phase 1 clinical development and has not been approved by the FDA.
PARP Inhibitor BGB-290 targets poly (ADP-ribose) polymerase (PARP) enzymes, which are involved in DNA repair. By inhibiting PARP, the drug is designed to exploit DNA repair deficiencies in tumor cells, potentially making them more susceptible to DNA-damaging agents like temozolomide.
PARP Inhibitor BGB-290 is being developed by BeOne Medicines Ltd., a biopharmaceutical company traded under the ticker ONC. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with glioblastoma and other IDH-mutant gliomas.
PARP Inhibitor BGB-290 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials to determine its safety, dosing, and potential efficacy.
PARP Inhibitor BGB-290 is being studied in a Phase 1 clinical trial with the identifier NCT03749187. The trial, titled 'BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas,' is active but not recruiting and has an enrollment of 78 participants in the United States.
PARP Inhibitor BGB-290 is also known as pamiparib. The drug is being investigated under the name BGB-290 in clinical trials, and pamiparib is an alternative name used to refer to the same investigational compound.